Early pharmacologic treatment in Parkinson's disease
Hauser, RA. 2010. “Early Pharmacologic Treatment in Parkinson’s Disease”. Am J Manag Care.
Search
Search results
373 results found
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease
Bronzova, J, C Sampaio, RA Hauser, AE Lang, O Rascol, A Theeuwes, SV Van De Witte, and G van Scharrenburg. 2010. “Double-Blind Study of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinson’s Disease”. Mov Disord.
Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease
Watts, RL, KE Lyons, R Pahwa, K Sethi, M Stern, RA Hauser, W Olanow, AM Gray, B Adams, and NL Earl. 2010. “Onset of Dyskinesia With Adjunct Ropinirole Prolonged-Release or Additional Levodopa in Early Parkinson’s Disease”. Mov Disord.
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
Hauser, RA, KE Lyons, T McClain, S Carter, and D Perlmutter. 2009. “Randomized, Double-Blind, Pilot Evaluation of Intravenous Glutathione in Parkinson’s Disease”. Mov Disord.
Gary's Story: An Elusive Diagnosis - Parkinson's
Chorea induced by lamotrigine.
Zesiewicz, TA, KL Sullivan, and RA Hauser. 2006. “Chorea Induced by Lamotrigine.”. J Child Neurol.
Vascular hemichorea/hemiballismus and topiramate.
Zesiewicz, TA, KL Sullivan, and RA Hauser. 2006. “Vascular Hemichorea/Hemiballismus and Topiramate.”. Movement Disorders.
Long-term evaluation of deep brain stimulation of the thalamus.
Pahwa, R, KE Lyons, SB Wilkinson, RK Simpson Jr, WG Ondo, RA Hauser, and . 2006. “Long-Term Evaluation of Deep Brain Stimulation of the Thalamus.”. J Neurosurg.
Levetiracetam for stiff-person syndrome: report of 2 patients
Shimberg, WR, NB Patel, KL Sullivan, RA Hauser, and TA Zesiewicz. 2008. “Levetiracetam for Stiff-Person Syndrome: Report of 2 Patients”. Clin Neuropharmacol.
Optimizing bioavailability in the treatment of Parkinson’s disease.
Seeberger, LC, and RA Hauser. 2007. “Optimizing Bioavailability in the Treatment of Parkinson’s Disease.”. Neuropharmacology.